Alembic Pharmaceuticals receives USFDA final approval for Bosentan Tablets

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bosentan Tablets, 62.5 mg and 125 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Tracleer Tablets, 62.5 mg and 125 mg, of Actelion Pharmaceuticals. Bosentan Tablets indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1 ).

Bosentan Tablets, 62.5 mg and 125 mg have an estimated market size of US$ 68 million for twelve months ending September 2019 according to IQVIA.

Powered by Capital Market - Live News